EBS · Emergent BioSolutions Inc.
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-02-25 | $50,000,000 | — | — | 2027-03-31 | 8-K , filed 2026-04-30 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-06-30 YTD | $18,000,000 | 10-Q, filed 2026-08-06 | ||
| 2025-12-31 | $24,900,000 | 10-K, filed 2026-02-27 | ||
| 2024-12-31 | $0 | 10-K, filed 2026-02-27 | ||
| 2023-12-31 | $0 | 10-K, filed 2026-02-27 | ||
| 2022-12-31 | $82,100,000 | 10-K, filed 2025-03-04 | ||
| 2021-12-31 | $106,000,000 | 10-K, filed 2024-03-08 | ||
| 2020-12-31 | $0 | 10-K/A, filed 2023-12-11 | ||
| 2019-12-31 | $0 | 10-K, filed 2022-02-25 | ||
| 2018-12-31 | $100,000 | 10-K, filed 2021-02-19 | ||
| 2017-12-31 | $33,100,000 | 10-K, filed 2020-02-25 | ||
| 2016-12-31 | $0 | 10-K, filed 2019-02-22 | ||
| 2015-12-31 | $100,000 | 10-K, filed 2018-02-23 | ||
| 2014-12-31 | $200,000 | 10-K, filed 2017-02-28 | ||
| 2013-12-31 | $213,000 | 10-K, filed 2016-02-29 | ||
| 2012-12-31 | $5,906,000 | 10-K, filed 2015-03-09 | ||